AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29430176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26444030 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continuing for 24 h after surgery.
Number of subjects: 200
Study 26444030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 26444030 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 200
Study 24740205 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of citrus, green vegetables, red meat, shellfish, fish, peanuts, rice, butter, coffee, beer, liquor, total alcohol, and multivitamins
Number of subjects: 502
Study 24740205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraindividual metabolite variability
Number of subjects: 502
Study 22176868 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy (VBT)
Number of subjects: 427
Study 22176868 — intervention group
Group type: COMPARATOR
Intervention: External beam pelvic radiotherapy (EBRT)
Number of subjects: 427
Study 20964833 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 40
Study 20964833 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine and hydroxychloroquine (treatment A)
Number of subjects: 40
Study 20964833 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 20964833 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (treatment B)
Number of subjects: 40
Study 17347185 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 microg ml‐1
Number of subjects: 54
Study 17347185 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine 4.5 mg ml‐1
Number of subjects: 54
Study 16329017 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator training with the AccuTouch flexible endoscopy simulator
Number of subjects: 24
Study 16329017 — intervention group
Group type: COMPARATOR
Intervention: Control group (no simulator training)
Number of subjects: 24
Study 12077742 — intervention group
Group type: EXPERIMENTAL
Intervention: High-isoflavone soy diet (73 mg/d isoflavone)
Number of subjects: 41
Study 12077742 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-isoflavone soy diet (10 mg/d isoflavone)
Number of subjects: 41
Study 12077742 — intervention group
Group type: COMPARATOR
Intervention: Low-fat dairy food control phase
Number of subjects: 41
Study 12077742 — intervention group
Group type: EXPERIMENTAL
Intervention: High-isoflavone soy diet
Number of subjects: 41
Study 12077742 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-isoflavone soy diet
Number of subjects: 41
Study 9794350 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training group (3 times a week, averaging 83% of maximum heart rate)
Number of subjects: 109
Study 9794350 — intervention group
Group type: COMPARATOR
Intervention: Contact control group (nonexercising, 3 supervised health education lectures per week)
Number of subjects: 109
Study 8588499 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase related external suction (PRES) method
Number of subjects: 10
Study 8588499 — intervention group
Group type: COMPARATOR
Intervention: Conventional neck suction technique
Number of subjects: 10
Study 8588499 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 10
Study 8588499 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive Finapres blood pressure device
Number of subjects: 10
Study 2911850 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term doxorubicin infusion (10 mg/m2/day for 5 days)
Number of subjects: 15
Study 2911850 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term doxorubicin infusion (3 mg/m2/day for 5-104 days)
Number of subjects: 15
Study 2911850 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term doxorubicin infusion
Number of subjects: 15
Study 2911850 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term doxorubicin infusion
Number of subjects: 15
Study 2911850 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of doxorubicin
Number of subjects: 15
Study 1100969 — intervention group
Group type: EXPERIMENTAL
Intervention: DADDS
Number of subjects: 50
Study 1100969 — intervention group
Group type: COMPARATOR
Intervention: DDS
Number of subjects: 50
Study 31424962 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal extracts (mangosteen, Lithospermum officinale, Tribulus terrestris L., Houttuynia cordata Thunb)
Number of subjects: 60
Study 31424962 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 60
Study 31254717 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterconditioning with positive film clips
Number of subjects: 177
Study 31254717 — intervention group
Group type: COMPARATOR
Intervention: Standard extinction training
Number of subjects: 177
Study 31254717 — intervention group
Group type: COMPARATOR
Intervention: Extinction training with non-contingent exposure to positive film clips
Number of subjects: 177
Study 27489211 — intervention group
Group type: EXPERIMENTAL
Intervention: TV‐1106 (7.5, 15, 50, and 100 mg)
Number of subjects: 88
Study 27489211 — intervention group
Group type: EXPERIMENTAL
Intervention: TV‐1106 (7.5 and 15 mg)
Number of subjects: 88
Study 27489211 — intervention group
Group type: EXPERIMENTAL
Intervention: TV‐1106 (50 and 100 mg)
Number of subjects: 88
Study 27489211 — intervention group
Group type: EXPERIMENTAL
Intervention: TV‐1106
Number of subjects: 88
Study 26409167 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidised healthcare
Number of subjects: 2151
Study 26409167 — intervention group
Group type: COMPARATOR
Intervention: Control group (no subsidised care)
Number of subjects: 2151
Study 22610853 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids (1 g/day)
Number of subjects: 30
Study 22610853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17047181 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutured securement
Number of subjects: 66
Study 17047181 — intervention group
Group type: COMPARATOR
Intervention: Tape securement
Number of subjects: 66
Study 14679674 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose perindopril/indapamide (2 mg and 0.625 mg daily)
Number of subjects: 533
Study 14679674 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment of atenolol (50 mg) then losartan (50 mg) then amlodipine (5 mg)
Number of subjects: 533
Study 14679674 — intervention group
Group type: COMPARATOR
Intervention: Step-by-step strategy of valsartan (40 mg then 80 mg then 80 mg plus hydrochlorothiazide 12.5 mg)
Number of subjects: 533
Study 10989766 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (150 mg ferrous sulfate tablets, 50 mg Fe daily)
Number of subjects: 520
Study 10989766 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly iron supplementation (150 mg ferrous sulfate tablets, 50 mg Fe twice weekly)
Number of subjects: 520
Study 10989766 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly iron supplementation (150 mg ferrous sulfate tablets, 50 mg Fe once weekly)
Number of subjects: 520
Study 10989766 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iron supplement)
Number of subjects: 520
Study 8781867 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy weight training
Number of subjects: 27
Study 8781867 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 1534832 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term sodium restriction (daily sodium intake reduced to less than 70 mmol)
Number of subjects: 40
Study 1534832 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term sodium restriction
Number of subjects: 40
Study 1534832 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sodium restriction)
Number of subjects: 40
Study 6691613 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular course
Number of subjects: 104
Study 6691613 — intervention group
Group type: COMPARATOR
Intervention: Lecture course
Number of subjects: 104
Study 6691613 — intervention group
Group type: EXPERIMENTAL
Intervention: Refresher course after one year
Number of subjects: 104
Study 6691613 — intervention group
Group type: COMPARATOR
Intervention: No refresher course
Number of subjects: 104
Study 31782367 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh pomegranate juice (1.5 mL kg‐1)
Number of subjects: 89
Study 30939143 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based patient-centered intervention delivered by a clinical pharmacist
Number of subjects: 1400
Study 30939143 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 1400
Study 28262269 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding hip screw
Number of subjects: 1108
Study 28262269 — intervention group
Group type: COMPARATOR
Intervention: Cancellous screws
Number of subjects: 1108
Study 26385340 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face individual MI
Number of subjects: 495
Study 26385340 — intervention group
Group type: EXPERIMENTAL
Intervention: Online group MI
Number of subjects: 495
Study 26385340 — intervention group
Group type: COMPARATOR
Intervention: Health education (HE)
Number of subjects: 495
Study 23561008 — intervention group
Group type: EXPERIMENTAL
Intervention: Okoubaka aubrevillei (potency C12)
Number of subjects: 31
Study 23561008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sucrose globules)
Number of subjects: 31
Study 23561008 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis
Number of subjects: 31
Study 23561008 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative comparison of symptom profiles
Number of subjects: 31
Study 21392615 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF/FGF plasmid (n = 33)
Number of subjects: 52
Study 21392615 — intervention group
Group type: COMPARATOR
Intervention: Placebo plasmid (n = 19)
Number of subjects: 52
Study 19479153 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml of 0.25% bupivacaine
Number of subjects: 8
Study 19479153 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 8
Study 17229221 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutritional therapy (EN group)
Number of subjects: 40
Study 17229221 — intervention group
Group type: COMPARATOR
Intervention: Non-nutritional therapy (non-EN group)
Number of subjects: 40
Study 15535487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine 0.25 mg/kg with glycopyrrolate 0.01 mg/kg at 5 minutes after rocuronium administration
Number of subjects: 51
Study 15535487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine 0.25 mg/kg with glycopyrrolate 0.01 mg/kg at 1% twitch height (T1) recovery
Number of subjects: 51
Study 15535487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine 0.25 mg/kg with glycopyrrolate 0.01 mg/kg at 25% twitch height (T25) recovery
Number of subjects: 51
Study 15535487 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous recovery group
Number of subjects: 51
Study 15535487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine groups (T1 and T25)
Number of subjects: 51
Study 11555061 — intervention group
Group type: EXPERIMENTAL
Intervention: Preintervention treatment with parenteral antibiotics (PA) when PA were recommended by the guidelines (n = 127)
Number of subjects: 350
Study 11555061 — intervention group
Group type: EXPERIMENTAL
Intervention: Preintervention treatment with oral antibiotics (OA) when OA were indicated by the guidelines (n = 99)
Number of subjects: 350
Study 11555061 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintervention treatment with PA and OA according to the guidelines
Number of subjects: 350
Study 11555061 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintervention episodes treated with PA in accordance with the guidelines
Number of subjects: 350
Study 11555061 — intervention group
Group type: EXPERIMENTAL
Intervention: Preintervention episodes with indications for PA
Number of subjects: 350
Study 11555061 — intervention group
Group type: EXPERIMENTAL
Intervention: Preintervention episodes with indications for OA
Number of subjects: 350
Study 11555061 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintervention episodes with indications for PA
Number of subjects: 350
Study 11555061 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintervention episodes with indications for OA
Number of subjects: 350
Study 11555061 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of 30-day mortality preintervention and postintervention for episodes with guideline indications for OA
Number of subjects: 350
Study 11555061 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of 30-day mortality preintervention and postintervention for episodes with guideline indications for PA
Number of subjects: 350
Study 11555061 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of 30-day mortality
Number of subjects: 350
Study 11555061 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital admissions for episodes on NHAP
Number of subjects: 350
Study 10021958 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml saline
Number of subjects: 70
Study 10021958 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml saline
Number of subjects: 70
Study 10021958 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml saline
Number of subjects: 70
Study 7917685 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 20
Study 7917685 — intervention group
Group type: COMPARATOR
Intervention: Intermittent ischaemic arrest
Number of subjects: 20
Study 3379782 — intervention group
Group type: COMPARATOR
Intervention: VEPA (vincristine, cyclophosphamide, prednisolone and doxorubicin)
Number of subjects: 82
Study 3379782 — intervention group
Group type: EXPERIMENTAL
Intervention: VEPA-M (VEPA plus methotrexate)
Number of subjects: 82
Study 3379782 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group
Number of subjects: 82
Study 3379782 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-risk group
Number of subjects: 82
Study 3379782 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 82
Study 31122721 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients born in November
Number of subjects: 12263
Study 31122721 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients born in December
Number of subjects: 12263
Study 31122721 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients born in February
Number of subjects: 12263
Study 31122721 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients born in January to March and May to September
Number of subjects: 12263
Study 31122721 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients born in winter
Number of subjects: 12263
Study 31122721 — intervention group
Group type: COMPARATOR
Intervention: Patients across birth seasons
Number of subjects: 12263
Study 29234746 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 or 6 mm long implants
Number of subjects: 20
Study 29234746 — intervention group
Group type: COMPARATOR
Intervention: 10 mm long implants
Number of subjects: 20
Study 26323921 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab (200 mg) with docetaxel (60 mg/m2) and carboplatin (AUC = 5)
Number of subjects: 59
Study 26323921 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (docetaxel 60 mg/m2 and carboplatin AUC = 5)
Number of subjects: 59
Study 26323921 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab with chemotherapy
Number of subjects: 59
Study 23447123 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin administered according to the customary insulin:carbohydrate ratio
Number of subjects: 19
Study 21672597 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from 9-10 mg ISO tar yield cigarette to 4 mg ISO tar yield cigarette
Number of subjects: 300
Study 21672597 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from 4-6 mg ISO tar yield cigarette to 1 mg ISO tar yield cigarette
Number of subjects: 300
Study 21672597 — intervention group
Group type: COMPARATOR
Intervention: Non-switching control group smoking their usual ISO tar yield cigarette
Number of subjects: 300
Study 19929644 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm and lubricant gel intervention
Number of subjects: 0
Study 17036703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) pulpotomy
Number of subjects: 15
Study 17036703 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide (Ca(OH)2) pulpotomy
Number of subjects: 15
Study 15679256 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted drugs in combination with ionizing radiation
Number of subjects: 0
Study 15679256 — intervention group
Group type: COMPARATOR
Intervention: Ionizing radiation alone
Number of subjects: 0
Study 10678543 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor ramipril (5 mg/day for 3 weeks)
Number of subjects: 9
Study 10678543 — intervention group
Group type: EXPERIMENTAL
Intervention: AT1B losartan (50 mg/day for 3 weeks)
Number of subjects: 9
Study 10678543 — intervention group
Group type: COMPARATOR
Intervention: Control L-arginine infusion
Number of subjects: 9
Study 10678543 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor ramipril and AT1B losartan
Number of subjects: 9
Study 9549634 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril/Diltiazem ER alone (n = 14)
Number of subjects: 93
Study 9549634 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril/Diltiazem ER with other agents (n = 79)
Number of subjects: 93
Study 8349942 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen challenge
Number of subjects: 15
Study 8349942 — intervention group
Group type: COMPARATOR
Intervention: Diluent challenge
Number of subjects: 15
Study 3484691 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin, 0.375 mg/day, loaded with doubled doses on days 1 and 2, for 14 days.
Number of subjects: 48
Study 3484691 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil, 300 mg/day, loaded with 900 mg on day 8.
Number of subjects: 48
Study 3484691 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent dosing of digoxin and bepridil.
Number of subjects: 48
Study 3484691 — intervention group
Group type: COMPARATOR
Intervention: Digoxin alone.
Number of subjects: 48
Study 3484691 — intervention group
Group type: COMPARATOR
Intervention: Bepridil alone.
Number of subjects: 48
Study 3484691 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent dosing of both drugs.
Number of subjects: 48
Study 28322651 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual care
Number of subjects: 62
Study 28322651 — intervention group
Group type: COMPARATOR
Intervention: Control group (no spiritual care)
Number of subjects: 62
Study 26092233 — intervention group
Group type: EXPERIMENTAL
Intervention: lipegfilgrastim 6 mg
Number of subjects: 202
Study 26092233 — intervention group
Group type: COMPARATOR
Intervention: pegfilgrastim 6 mg
Number of subjects: 202
Study 24694622 — intervention group
Group type: EXPERIMENTAL
Intervention: Well London interventions (activities focused on healthy eating, physical exercise, and mental health and well-being)
Number of subjects: 61
Study 22647280 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair-rising exercise
Number of subjects: 30
Study 22647280 — intervention group
Group type: COMPARATOR
Intervention: One-leg standing exercise
Number of subjects: 30
Study 19896200 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-ChORD (integrative treatment program including medication management, interpersonal psychotherapy, and occupational therapy)
Number of subjects: 64
Study 19896200 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 64
Study 18847162 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine-treated patients
Number of subjects: 38
Study 18847162 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study 16181936 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture needles
Number of subjects: 51
Study 16181936 — intervention group
Group type: COMPARATOR
Intervention: Telescopic sham needles
Number of subjects: 51
Study 11936063 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based aerobic exercise intervention (15 weeks, 20 minutes three times per week)
Number of subjects: 99
Study 11936063 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 99
Study 10556613 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopic subjects
Number of subjects: 0
Study 10556613 — intervention group
Group type: COMPARATOR
Intervention: Emmetropic control subjects
Number of subjects: 0
Study 8918674 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine administration of rG‐CSF on the 6th day after BEP chemotherapy (group A)
Number of subjects: 15
Study 8918674 — intervention group
Group type: COMPARATOR
Intervention: Administration of rG‐CSF after granulocytopenia of 1,500/mm3 had developed (group B)
Number of subjects: 15
Study 8918674 — intervention group
Group type: COMPARATOR
Intervention: BEP chemotherapy
Number of subjects: 15
Study 8918674 — intervention group
Group type: EXPERIMENTAL
Intervention: rG‐CSF in group A
Number of subjects: 15
Study 1747882 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste with sodium monofluorophosphate, calcium glycerophosphate supplement, and calcium carbonate abrasive
Number of subjects: 19
Study 1747882 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste with sodium monofluorophosphate and sodium fluoride, calcium glycerophosphate supplement, and calcium carbonate abrasive
Number of subjects: 19
Study 1747882 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste with sodium fluoride and silica abrasive
Number of subjects: 19
Study 1747882 — intervention group
Group type: COMPARATOR
Intervention: Fluoride-free toothpaste with silica abrasive
Number of subjects: 19
Study 6817771 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 27
Study 6817771 — intervention group
Group type: EXPERIMENTAL
Intervention: Clovoxamine
Number of subjects: 27
Study 6817771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 30950535 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based life review program plus routine care
Number of subjects: 92
Study 30950535 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 92